Top News

Attorney says 'no chance' that $140 million punitive damages judgment against AbbVie will stand

Elizabeth Alt Nov. 9, 2017, 12:47pm

North Chicago-based drugmaker AbbVie has asked a federal judge to toss out a $140 million verdict against it for allegedly mismarketing its testosterone replacement therapy drug, Androgel. And in the view of a Chicago attorney whose practice focuses on Supreme Court and appellate cases, as well as class actions, there is "no chance" that judgment will be allowed to stand.

Drug maker AbbVie wants to slip from $140M verdict, says jury ignored evidence

Dan Churney Nov. 6, 2017, 12:22pm

North Chicago-based drug company AbbVie is urging a federal judge to trash a verdict ordering it to cough up $140 million, because its testosterone therapy drug AndroGel contributed to a man's heart attack, contending it has no liability because AndroGel was approved by the FDA.

Jury: Abbvie falsely marketed Androgel, owes man who suffered heart attack $140M

Jonathan Bilyk Oct. 5, 2017, 11:46pm

Drugmaker Abbvie has suffered another big loss in court, as a Chicago federal jury has ordered the North Chicago-based pharmaceutical company to pay out $140 million to another man who claimed he had suffered a heart attack as a result of taking Abbvie’s testosterone therapy drug, Androgel.

Jury: AbbVie should pay $150M for Androgel marketing; AbbVie: Verdict won't stand

Jonathan Bilyk Jul. 24, 2017, 6:47pm

A federal jury has ordered drugmaker AbbVie to pay $150 million in damages for allegedly falsely marketing the benefits of its Androgel testosterone therapy drug, even though the jury did not hold the company liable for a heart attack suffered by a man taking the drug.

Label or Liability: Case law could lead to short shelf life for $3M Paxil 'innovator liability' verdict

Stephanie N. Grimoldby Jun. 13, 2017, 11:00am

A Chicago federal jury shocked many observers by ordering drugmaker GlaxoSmithKline to pay $3 million to the widow of lawyer Stewart Dolin, who committed suicide in 2010 after taking a generic version of GSK's antidepressant Paxil. But legal observers believe the decision may have a short shelf life, as it could defy decades of case law on the concept of innovator liability.

Federal judge tosses some accusations vs testosterone drug makers on eve of Androgel bellwether trials

Dan Churney May 16, 2017, 3:34pm

A Chicago federal judge has dismissed several. but not all of the claims against the maker of a testosterone boosting drug, advanced by several plaintiffs chosen as bellwethers in a class-action lawsuit brought by more than 2,000 plaintiffs from around the U.S. against multiple drug manufacturers, including Besins, AbbVie, Eli Lilly and GlaxoSmithKline.

Consumers too far down distribution chain to press price fixing class action vs steelmakers, says judge

Dan Churney Mar. 13, 2017, 9:10pm

A group of steel makers, led by Chicago-based ArcelorMittal USA, have beaten down a class-action antitrust lawsuit filed by more than a dozen consumers, who alleged the companies schemed to raise prices for goods made with steel, by pointing out the consumers were too far down the distribution line from the steel manufacturers to claim losses. 

Some market manipulation claims vs Opana maker chopped under IL law, other states' laws

Dan Churney Aug. 22, 2016, 9:28am

A Chicago federal judge has chopped a few counts from a huge putative class-action suit – based on laws of various states, including Illinois – accusing the maker of the prescription pain killer Opana of improperly keeping the price of its product high by paying off another pharmaceutical company to delay the release of a generic version of the drug.

Judge says Walgreen, Rite Aid must show numbers to push allegations Opana drugmakers cheated them

Dan Churney Mar. 7, 2016, 1:09pm

A Chicago federal judge has kicked drug retailers Walgreen and Rite Aid from an antitrust lawsuit against the maker of prescription pain killer Opana, saying the retailers must provide hard dollar figures to back up their allegations that the drugmaker improperly paid off another pharmaceutical company to delay the release of the generic version of its pain killer, and keep the price of its name brand drug high.